KRAS gene mutations were considered to be “untargetable” until 2021, when the first KRAS inhibitor—sotorasib—was approved for use in NSCLC patients, who were treated with at least one systemic treatment and progressed. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.